Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Rubicon Organics (OtherROMJF), Alcon (ALC) and Milestone Pharmaceuticals (MIST)

Tipranks - Tipranks - Thu Mar 26, 8:43AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rubicon Organics (ROMJF), Alcon (ALC) and Milestone Pharmaceuticals (MIST) with bullish sentiments.

Claim 30% Off TipRanks Premium

Rubicon Organics (ROMJF)

In a report released yesterday, Nicholas Cortellucci from Atrium Research maintained a Buy rating on Rubicon Organics, with a price target of C$1.00. The company’s shares closed last Tuesday at $0.34.

According to TipRanks.com, Cortellucci is ranked #11328 out of 12128 analysts.

Rubicon Organics has an analyst consensus of Moderate Buy, with a price target consensus of $0.84, implying a 142.9% upside from current levels. In a report released yesterday, Haywood also maintained a Buy rating on the stock with a C$1.30 price target.

See today’s best-performing stocks on TipRanks >>

Alcon (ALC)

BTIG analyst Ryan Zimmerman maintained a Buy rating on Alcon on March 23 and set a price target of $92.00. The company’s shares closed last Wednesday at $75.12.

According to TipRanks.com, Zimmerman is a 1-star analyst with an average return of -0.4% and a 40.0% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Shoulder Innovations, Inc., and Tactile Systems Technology. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alcon with a $95.95 average price target, implying a 29.2% upside from current levels. In a report issued on March 11, UBS also maintained a Buy rating on the stock with a CHF95.00 price target.

Milestone Pharmaceuticals (MIST)

TD Cowen analyst Ritu Baral maintained a Buy rating on Milestone Pharmaceuticals on March 23 and set a price target of $8.00. The company’s shares closed last Wednesday at $1.19.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 43.2% and a 53.6% success rate. Baral covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Praxis Precision Medicines, and Sionna Therapeutics, Inc. ;'>

Currently, the analyst consensus on Milestone Pharmaceuticals is a Moderate Buy with an average price target of $8.00, which is a 589.7% upside from current levels. In a report issued on March 20, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.00 price target.

Read More on ROMJF:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).